Advances in Precision Oncology: From Molecular Profiling to Regulatory-Approved Targeted Therapies
Open Access
Abstract
The rapid evolution of sequencing technologies has profoundly advanced precision oncology. Whole-exome sequencing (WES), whole-genome sequencing (WGS), and whole-transcriptome sequencing (RNA-Seq) enable comprehensive characterization of tumor biology by detecting actionable mutations, gene fusions, splice variants, copy number alterations, and pathway dysregulation. These approaches also provide critical insights into biomarkers such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI), which are increasingly essential for guiding therapeutic decisions. Importantly, comprehensive genomic profiling not only refines patient stratification for targeted therapies but also sheds light on tumor–immune interactions and the tumor microenvironment, paving the way for more effective immunotherapeutic combinations. WGS is considered the gold standard for detecting germline mutations and complex structural variants, while WES remains central for detecting somatic driver mutations that guide targeted therapies. RNA-Seq complements these methods by capturing gene expression dynamics, identifying clinically relevant fusions, and revealing mechanisms of resistance. Together with advances in bioinformatics and artificial intelligence, these tools translate molecular data into actionable strategies for patient care. This review integrates insights from WGS, WES, and RNA-Seq with an overview of FDA- and EMA-approved targeted therapies, organized by tumor type, and highlights the molecular signaling pathways that drive cancer development and treatment. By bridging genomic profiling with regulatory-approved therapies, we outline current advances and future perspectives in delivering personalized cancer care.Keywords
This publication has 179 references indexed in Scilit:
- Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practiceClinical and Translational Medicine, 2025
- Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology, 2024
- Spatial transcriptomics in cancer research and potential clinical impact: a narrative reviewJournal of Cancer Research and Clinical Oncology, 2024
- Wnt signaling in cell adhesion, development, and colon cancerIUBMB Life, 2024
- The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated reviewVirchows Archiv, 2023
- Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspectiveJournal of Cancer Research and Clinical Oncology, 2023
- Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019JAMA Network Open, 2022
- Cancer of the ovary, fallopian tube, and peritoneum: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- Alitretinoin in the treatment of cutaneous T‐cell lymphomaCancer Medicine, 2021
- Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyondMolecular Carcinogenesis, 2017